Enhancement of the Effects of 5-Fluorouracil

  • R. Herrmann
Conference paper
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 100)


5-Fluorouracil (5-FU) is one of the few anticancer agents that has been developed on a rational basis [10]. Although it has been clinically used since the late 1950s, 5-FU has recently attracted new interest because of two developments:
  1. 1.

    Methods have been developed which allow the detection of small amounts of 5-FU and most of its metabolites.

  2. 2.

    There has been a revival of regional drug administration, especially hepatic artery infusion. Since 5-FU is metabolized in the liver to a significant degree, it is one of the drugs used for this administration.



Clin Oncol L1210 Cell Sequential Combination Thymidylate Synthetase Hepatic Artery Infusion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bertino JR, Sawicki WL, Lindquist CA, Gupta VS (1977) Schedule-dependent antitumor effects of methotrexate and 5-fluorouracil. Cancer Res 37: 327–328PubMedGoogle Scholar
  2. 2.
    Blumenreich MS, Woodcock TM, Allegra M, Richman SP, Kubota TT, Allegra IC (1982) Sequential therapy with methotrexate and 5-fluorouracil for adenocarcinoma of the colon. Proc Am Soc Clin Oncol 18: 102 (Abstr)Google Scholar
  3. 3.
    Burnet R, Smith FP, Hoerni B, Lagarde C, Schein P (1981) Sequential methotrexate-5-fluorouracil in advanced measurable colorectal cancer: lack of appreciable therapeutic synergism. Proc Am Soc Clin Oncol 17: 370 (Abstr)Google Scholar
  4. 4.
    Cadman E, Heimer R, Benz C (1981) The influence of methotrexate pretreatment on 5-fluorouracil metabolism in L1210 cells. J Biol Chem 256: 1695–1704PubMedGoogle Scholar
  5. 5.
    Cantell JE, Burnet R, Lagarde C, Schein PS, Smith FP (1982) Phase II study of sequential methotrexate-5-FU therapy in advanced measurable colorectal cancer. Cancer Treat Rep 66: 1563–1565Google Scholar
  6. 6.
    Carrico CK, Glazer RI (1979) Effect of 5-fluorouracil on the synthesis and translation of polyadenylic acid-containing RNA from regenerating rat liver. Cancer Res 39: 3694–3701PubMedGoogle Scholar
  7. 7.
    Coates AS, Hedley D, Fox RM, Raghavan D, Tattersall MHN (1983) Randomised trial of sequential methotrexate (M) followed by 5-fluorouracil (F) versus F followed by M. Proc Am Assoc Cancer Res 74: 140 (Abstr)Google Scholar
  8. 8.
    Fernandes DJ, Bertino JR (1980) 5-fluorouracil-methotrexate synergy: enhancement of 5-fluorodeoxyuridylate binding to thymidylate synthetase by dihydropteroyl-polyglutamates. Proc Natl Acad Sci USA 77: 5663–5667PubMedCrossRefGoogle Scholar
  9. 9.
    Hartman KU, Heidelberger C (1961) Studies on fluorinated pyrimidines. VIII. Inhibition of thymidylate synthetase. J Biol Chem 236: 3006–3013Google Scholar
  10. 10.
    Heidelberger C, Chandhuri NK, Danenberg P, Mooren D, Griesbach L, Duschinsky R, Schnitzer J, Pleven E, Scheiner J (1957) Fluorinated pyrimidines, a new class of tumor-inhibitory compounds. Nature 179: 663–666PubMedCrossRefGoogle Scholar
  11. 11.
    Herrmann R, Spehn J, Beyer JH, von Franque U, Schmieder A, Holzmann K, Abel U (1984a) Sequential methotrexate and 5-fluorouracil. Improved response rate in metastatic clorectal cancer. J Clin Oncol 2: 591–594Google Scholar
  12. 12.
    Herrmann R, Manegold C, Schroeder M, Tigges FJ, Bartsch H, Jungi F, Fritze D (1984b) Sequential methotrexate and 5-fluorouracil in breast cancer resistant to the conventional application of these drugs. Cancer Treat Rep 68: 1279–1281Google Scholar
  13. 13.
    Herrmann R, Kunz W, Osswald H, Ritter M, Port RD (1985) The effect of methotrexate pretreatment on 5-fluorouracil kinetics in sarcoma 180 in vivo. Eur J Cancer Clin Oncol 21: 753–758PubMedCrossRefGoogle Scholar
  14. 14.
    Kufe DW, Egan EM (1981) Enhancement of 5-fluorouracil incorporation into human lymphoblast ribonucleic acid. Biochem Pharmacol 30: 129–133PubMedCrossRefGoogle Scholar
  15. 15.
    Panasci L, Margolese R (1982) Sequential methotrexate and 5-fluorouracil in breast and colorectal cancer. Results of increasing the dose of FU. Proc Am Soc Clin Oncol 18: 101 (Abstr)Google Scholar
  16. 16.
    Piper AA, Nott SE, Mackinnon WB, Tattersall MHN (1983) Critical modulation by thymidine and hypoxanthine of sequential methotrexate-5-fluorouracil synergism in murine L1210 cells. Cancer Res 43: 5701–5705Google Scholar
  17. 17.
    Wayss K, Herrmann R, Mattem J, Volm M (1985) Sequential methotrexate and 5-fluorouracil in human tumor xenografts. Med Oncol Tumor Pharmacother 2 (1): 27–32PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1986

Authors and Affiliations

  • R. Herrmann
    • 1
  1. 1.Medizinische KlinikKlinikum Charlottenburg der Freien UniversitätBerlin 19Germany

Personalised recommendations